Smart, cardiac-synchronized ECP technology with broad therapeutic reach
Pression’s Wave PROTM is redefining how external counterpulsation is delivered: mobile in the clinical space , validated, and scalable. A turnkey solution with little competition around a large unmet need in a growing market.
Company Overview
Unlocking Access To Non-Invasive Cardiac Therapy
Founded by Adam Salamon in 2019, Pression operates with an agile team with deep experience in engineering, commercialization and company building. Under his leadership, Pression unites experts in medical-device design, regulatory strategy, and commercialization to make heart-health technology truly accessible.
Our Mission
To deliver a non-invasive, quiet, comfortable, and affordable therapy for individuals suffering from drug-refractory chronic stable angina without revascularization options, while also enhancing circulation and VO₂ in healthy adults seeking better vascular performance. Our mission is to extend access to advanced heart care, improving quality of life through innovation in cardiovascular wellness.
Technology Platform
The Wave PROTM
platform stands apart for its:
Portability
At only 34 kg, the Wave PROTM is 90% lighter than traditional ECP systems and includes a small, wheeled footprint for easy portability across rooms or sites.
At only 34 kg, the Wave PROTM is 90% lighter than traditional ECP systems and includes a small, wheeled footprint for easy portability across rooms or sites.
Clinical proof
Equivalent performance to legacy systems demonstrated in the WaveCRESST trial1
Scalable platform
Architecture adaptable for future indications beyond angina, including vascular conditioning and wellness applications.
Regulatory readiness
510(k) cleared1
Commercial readiness
All pre-manufacturing processes are complete, supported by multiple Letters of Intent (LOIs) totaling a pipeline equivalent to ~$10 million in annual recurring revenue (ARR).
Go-to-market readiness
Dedicated sales team with extensive network and industry experience, and a robust sales pipeline positioning Pression for immediate market launch.
Market Opportunity
20M
Patents with Coronary Artery Disease7
1.7M
Patients Eligible for ECP Treatment8
$100B
Annual Costs of Chronic Stable Angina (CSA) Treatments9
Cardiovascular disease remains the world’s leading cause of death
Despite advances in therapy, many patients still lack access to effective, non-invasive treatment options, placing a growing burden on healthcare systems worldwide.
1960s–1980s
Early Development and Limited Adoption
Originally developed in the 1960s, external counterpulsation (ECP) showed early promise as a non-invasive therapy for angina. However, the technology saw little evolution, and early systems remained large, cumbersome, and rooted in their original full-lower body design.
1990s–2010s
FDA clearance and Minimal Innovation
Despite efforts to expand beyond its original U.S. clearance in the 2000s, ECP therapy remained largely confined to niche clinical use.. Systems remained bulky, immobile, and operationally demanding—requiring dedicated rooms, multiple staff touchpoints, and rigid workflows. With minimal engineering progress and high capital barriers, ECP stayed concentrated in specialized centers rather than integrating into everyday cardiovascular practice.
Today
A Modern Platform Built for Scalable Care
Today’s care environments require simpler, more accessible, and more scalable solutions. Wave PRO answers that need—not as another legacy ECP device, but as a smart gated compression platform designed for modern clinical workflows and future expandability. While our focus begins in cardiovascular care, the underlying architecture supports exploration in areas such as critical care hemodynamics, fluid responsiveness, diabetic wound healing, peripheral artery disease, and even sports performance and recovery. These are not current markets, but they reflect a platform with far broader potential than legacy ECP ever envisioned.
Join Us in Transforming Cardiac Care
Be part of the next generation of accessible cardiovascular innovation.
Disclaimer: This information may contain forward-looking statements that involve a number of risks and uncertainties. Actual results could materially differ from those anticipated. The content presented is for informational purposes only and should not be considered legal or investment advice. The information presented is true to the best of Pression’s knowledge, but is a summary only and should not be relied upon to make investment decisions but upon due diligence. Any investment in Pression is high risk; the units are not registered with the SEC or any state. Any viewer who is not legally allowed to invest must not view this information.
